Biomarker & Intervention Discovery

Prostate Cancer

This page lists 11 druggable gene targets, 47 approved or trial-tested drug candidates and 15 recent clinical trials for Prostate Cancer, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Prostate Cancer (2026): Drugs in Trials

US DALYs837.7KWHO GHE 2021 · all ages
Global DALYs7.74MWHO GHE 2021 · worldwide
US mortality37.3K deaths/yrWHO GHE 2021
Global mortality393.9K deaths/yrWHO GHE 2021 · worldwide
NIH funding$314MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionLow-grade (Gleason 6/Grade Group 1): active surveillance appropriate in 40-50% — many will never need treatment…
Best-intervention remissionLocalised: surgery (radical prostatectomy) or radiotherapy — 90-95% disease-specific survival at 10 years; mCSPC:…
Gap sizeLarge — active surveillance underused in low-risk disease (overtreatment); ADT monotherapy still used where…
Primary barrierpractice
Full remission profile →
Research Tracker Chronic Disease Interventions Prostate Cancer

Remission & chronicity

Spontaneous remission
Low-grade (Gleason 6/Grade Group 1): active surveillance appropriate in 40-50% — many will never need treatment; high-grade: lethal without treatment within 5-10 years
Best-intervention remission
Localised: surgery (radical prostatectomy) or radiotherapy — 90-95% disease-specific survival at 10 years; mCSPC: darolutamide + docetaxel + ADT (ARASENS): 32% OS improvement; enzalutamide/abiraterone + ADT as standard 2019-2021; PARP inhibitors for BRCA-mutant: olaparib — 34% OS benefit (PROfound)
Gap size
Large — active surveillance underused in low-risk disease (overtreatment); ADT monotherapy still used where combination therapy is standard
Primary barrier
practice
Active surveillance in low-risk PCa is guideline-endorsed but only 50-60% of eligible patients are managed this way (radical treatment used unnecessarily with significant sexual/urinary side effects); intensified ADT combinations are standard of care for mHSPC but ADT monotherapy still prescribed

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

AKT1 248AR 994BRCA1 283BRCA2 19CYP17A1 124FOLH1 188KLK3 208PARP1 207PTEN 155SRD5A2 145TMPRSS2 69

AKT1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FASUDIL ? unclear Mechanistic DGIdb
TOPOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
5-METHOXYCANTHINONE ? unclear Mechanistic DGIdb
IPATASERTIB ↓ inhibits Mechanistic DGIdb
MS15 ↓ inhibits Mechanistic DGIdb
NELFINAVIR ↓ inhibits Mechanistic DGIdb
XL418 ? unclear Mechanistic DGIdb
ENZASTAURIN ? unclear Mechanistic DGIdb
TRICIRIBINE ↓ inhibits Mechanistic DGIdb
PERIFOSINE ↓ inhibits Mechanistic DGIdb
M-2698 ↓ inhibits Mechanistic DGIdb
UPROSERTIB ↓ inhibits Mechanistic DGIdb
CANTHIN-6-ONE ? unclear Mechanistic DGIdb
CAPIVASERTIB ↓ inhibits Mechanistic DGIdb
CI-1040 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL480356 ? unclear Mechanistic DGIdb
ANDROGRAPHOLIDE ? unclear Mechanistic DGIdb
SR-13668 ↓ inhibits Mechanistic DGIdb
LAUROGUADINE ? unclear Mechanistic DGIdb
DABRAFENIB ? unclear Mechanistic DGIdb
GEFITINIB ? unclear Mechanistic DGIdb
EVEROLIMUS ↓ inhibits Mechanistic DGIdb
GIGANTOL ? unclear Mechanistic DGIdb
GSK690693 ↓ inhibits Mechanistic DGIdb
VAD-044 ~ modulates Mechanistic DGIdb
HU7691 ↓ inhibits Mechanistic DGIdb
LY-2780301 ↓ inhibits Mechanistic DGIdb
GAMBOGIC AMIDE ? unclear Mechanistic DGIdb
MIRANSERTIB ? unclear Mechanistic DGIdb
GEDATOLISIB ? unclear Mechanistic DGIdb
EUPALININ A ? unclear Mechanistic DGIdb
NINTEDANIB ESYLATE ? unclear Mechanistic DGIdb
GSK269962A ? unclear Mechanistic DGIdb
ERLOTINIB ? unclear Mechanistic DGIdb
CEP-11981 ? unclear Mechanistic DGIdb
OMIPALISIB ↓ inhibits Mechanistic DGIdb
A-674563 ↓ inhibits Mechanistic DGIdb
ARCHEXIN ? unclear Mechanistic DGIdb
CANERTINIB DIHYDROCHLORIDE ? unclear Mechanistic DGIdb
BARDOXOLONE METHYL ? unclear Mechanistic DGIdb

Showing top 40 of 248 agents ranked by evidence tier.

AR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AMI-1 ? unclear Mechanistic DGIdb
DIBEKACIN ? unclear Mechanistic DGIdb
CARBONYL CYANIDE M-CHLOROPHENYLHYDRAZONE ? unclear Mechanistic DGIdb
TRIPARANOL ? unclear Mechanistic DGIdb
DODINE ? unclear Mechanistic DGIdb
TANNIC ACID ? unclear Mechanistic DGIdb
DEFLAZACORT ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1235854 ? unclear Mechanistic DGIdb
ERGONOVINE ? unclear Mechanistic DGIdb
AMPEROZIDE HYDROCHLORIDE ? unclear Mechanistic DGIdb
ATROPINE METHYLBROMIDE ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE ? unclear Mechanistic DGIdb
BERBERINE CHLORIDE ? unclear Mechanistic DGIdb
NITRALIN ? unclear Mechanistic DGIdb
DEVAZEPIDE ? unclear Mechanistic DGIdb
MOCLOBEMIDE ? unclear Mechanistic DGIdb
GLPG0492 ~ modulates Mechanistic DGIdb
DEUTENZALUTAMIDE ↓ inhibits Mechanistic DGIdb
PRUXELUTAMIDE ↓ inhibits Mechanistic DGIdb
HEPTANE ? unclear Mechanistic DGIdb
THONZONIUM BROMIDE ? unclear Mechanistic DGIdb
FENHEXAMID ? unclear Mechanistic DGIdb
LEMILDIPINE ? unclear Mechanistic DGIdb
(R)-BICALUTAMIDE ? unclear Mechanistic DGIdb
MORICIZINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
METIPRANOLOL ? unclear Mechanistic DGIdb
FLUROCHLORIDONE ? unclear Mechanistic DGIdb
PYRIDOSTIGMINE BROMIDE ? unclear Mechanistic DGIdb
FLUTAMIDE ↓ inhibits Mechanistic 154.0 nM (IC50) DGIdb
CHEMBL:CHEMBL224318 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL423081 ? unclear Mechanistic DGIdb
PREDNISOLONE ? unclear Mechanistic 2760.0 nM (Ki) DGIdb
ORBIFLOXACIN ? unclear Mechanistic DGIdb
PROGESTERONE ? unclear Mechanistic 8.5 nM (Ki) DGIdb
FLUDIOXONIL ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1784521 ? unclear Mechanistic DGIdb
FLUMETHASONE ? unclear Mechanistic DGIdb
SERTRALINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
MELOXICAM ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL44011 ? unclear Mechanistic DGIdb

Showing top 40 of 994 agents ranked by evidence tier.

BRCA1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
7-HYDROXY ISOFLAVONE ? unclear Mechanistic DGIdb
OLAPARIB ? unclear Mechanistic DGIdb
PLATINUM COMPOUND ? unclear Mechanistic DGIdb
DAIDZIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL581929 ? unclear Mechanistic DGIdb
PIDNARULEX ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1481721 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL484663 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1214407 ? unclear Mechanistic DGIdb
2-PHENYLQUINOLINE ? unclear Mechanistic DGIdb
HARMALOL ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1574420 ? unclear Mechanistic DGIdb
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
MITOMYCIN ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
RESVERATROL ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL12658 ? unclear Mechanistic DGIdb
ONONIN ? unclear Mechanistic DGIdb
CEDIRANIB ? unclear Mechanistic DGIdb
PIPERINE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL446567 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL546649 ? unclear Mechanistic DGIdb
DEPHOSTATIN ? unclear Mechanistic DGIdb
SEMUSTINE ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1404865 ? unclear Mechanistic DGIdb
QUARFLOXIN ? unclear Mechanistic DGIdb
PARP/TANKYRASE INHIBITOR 2X-121 ? unclear Mechanistic DGIdb
WISTIN ? unclear Mechanistic DGIdb
CHRYSIN DIMETHYL ETHER ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL600315 ? unclear Mechanistic DGIdb
AURINTRICARBOXYLIC ACID ? unclear Mechanistic DGIdb
MITOXANTRONE HYDROCHLORIDE ? unclear Mechanistic DGIdb
SACITUZUMAB GOVITECAN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL588683 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL593254 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL588525 ? unclear Mechanistic DGIdb
PURPURIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL316796 ? unclear Mechanistic DGIdb

Showing top 40 of 283 agents ranked by evidence tier.

BRCA2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARBOPLATIN ? unclear Mechanistic DGIdb
OLAPARIB ? unclear Mechanistic DGIdb
TALAZOPARIB ? unclear Mechanistic DGIdb
NIRAPARIB ? unclear Mechanistic DGIdb
RUCAPARIB ? unclear Mechanistic DGIdb
QUARFLOXIN ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
VELIPARIB ? unclear Mechanistic DGIdb
BOSUTINIB ? unclear Mechanistic DGIdb
PLATINUM COMPOUND ? unclear Mechanistic DGIdb
TEMOZOLOMIDE ? unclear Mechanistic DGIdb
ENZALUTAMIDE ? unclear Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
PIDNARULEX ? unclear Mechanistic DGIdb
SACITUZUMAB GOVITECAN ? unclear Mechanistic DGIdb
CEDIRANIB ? unclear Mechanistic DGIdb
INIPARIB ? unclear Mechanistic DGIdb
PARP/TANKYRASE INHIBITOR 2X-121 ? unclear Mechanistic DGIdb

CYP17A1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
ORTERONEL ↓ inhibits Mechanistic DGIdb
ENZALUTAMIDE ? unclear Mechanistic DGIdb
GALETERONE ↓ inhibits Mechanistic DGIdb
ABIRATERONE-C6 OXIME ↓ inhibits Mechanistic DGIdb
ABIRATERONE ACETATE ↓ inhibits Mechanistic 17.0 nM (IC50) DGIdb
SEVITERONEL ? unclear Mechanistic DGIdb
LEVOKETOCONAZOLE ↓ inhibits Mechanistic DGIdb
LAPITERONEL ? unclear Mechanistic DGIdb
YXG-158 ↓ inhibits Mechanistic DGIdb
ABIRATERONE ? unclear Mechanistic 4.0 nM (IC50) Open Targets
CHEMBL138580 ↓ inhibits Mechanistic 1800.0 nM (IC50) ChEMBL
CHEMBL310690 ↓ inhibits Mechanistic 160.0 nM (IC50) ChEMBL
CHEMBL341591 ↓ inhibits Mechanistic 400.0 nM (IC50) ChEMBL
CHEMBL2111948 ↓ inhibits Mechanistic 1520.0 nM (IC50) ChEMBL
CHEMBL3137965 ↓ inhibits Mechanistic 74.0 nM (IC50) ChEMBL
CHEMBL2112781 ↓ inhibits Mechanistic 1250.0 nM (IC50) ChEMBL
CHEMBL357811 ↓ inhibits Mechanistic 27.0 nM (IC50) ChEMBL
CHEMBL2112888 ↓ inhibits Mechanistic 260.0 nM (IC50) ChEMBL
CHEMBL2111947 ↓ inhibits Mechanistic 540.0 nM (IC50) ChEMBL
CHEMBL3137967 ↓ inhibits Mechanistic 5.0 nM (IC50) ChEMBL
CHEMBL2112782 ↓ inhibits Mechanistic 970.0 nM (IC50) ChEMBL
CHEMBL432751 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL2112772 ↓ inhibits Mechanistic 1520.0 nM (IC50) ChEMBL
CHEMBL310315 ↓ inhibits Mechanistic 13.0 nM (IC50) ChEMBL
CHEMBL82926 ↓ inhibits Mechanistic 47.0 nM (IC50) ChEMBL
CHEMBL2112775 ↓ inhibits Mechanistic 2500.0 nM (IC50) ChEMBL
KETOCONAZOLE ↓ inhibits Mechanistic 740.0 nM (IC50) ChEMBL
CHEMBL3085257 ↓ inhibits Mechanistic 1800.0 nM (IC50) ChEMBL
CHEMBL2111951 ↓ inhibits Mechanistic 290.0 nM (IC50) ChEMBL
CHEMBL419743 ↓ inhibits Mechanistic 400.0 nM (IC50) ChEMBL
CHEMBL2112522 ↓ inhibits Mechanistic 21.0 nM (IC50) ChEMBL
CHEMBL2112517 ↓ inhibits Mechanistic 42.0 nM (IC50) ChEMBL
CHEMBL2112524 ↓ inhibits Mechanistic 100.0 nM (IC50) ChEMBL
CHEMBL2112526 ↓ inhibits Mechanistic 24.0 nM (IC50) ChEMBL
CHEMBL2112533 ↓ inhibits Mechanistic 400.0 nM (IC50) ChEMBL
CHEMBL2112519 ↓ inhibits Mechanistic 430.0 nM (IC50) ChEMBL
CHEMBL325307 ↓ inhibits Mechanistic 50.0 nM (IC50) ChEMBL
CHEMBL114864 ↓ inhibits Mechanistic 150.0 nM (IC50) ChEMBL
CHEMBL115944 ↓ inhibits Mechanistic 150.0 nM (IC50) ChEMBL

Showing top 40 of 124 agents ranked by evidence tier.

FOLH1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MERCAPTOPURINE ? unclear Mechanistic DGIdb
CAPROMAB ? unclear Mechanistic DGIdb
DIHYDROTESTOSTERONE ? unclear Mechanistic DGIdb
AUTOLOGOUS PSMA-4SCAR-EXPRESSING T-CELLS 4SCAR-PSMA ? unclear Mechanistic DGIdb
MLN-2704 ~ modulates Mechanistic DGIdb
METHOTREXATE ? unclear Mechanistic DGIdb
APVO-414 ? unclear Mechanistic DGIdb
J591 177LU ~ modulates Mechanistic DGIdb
CYT-500 177LU ~ modulates Mechanistic DGIdb
TECHNETIUM TC 99M TROFOLASTAT ? unclear Mechanistic DGIdb
MDX-070 ? unclear Mechanistic DGIdb
HUJ591 177LU ~ modulates Mechanistic DGIdb
SURAMIN ? unclear Mechanistic DGIdb
THERAPEUTIC ANDROGEN ? unclear Mechanistic DGIdb
MIPSAGARGIN ? unclear Mechanistic DGIdb
MLN-591RL ? unclear Mechanistic DGIdb
COMPOUND 8D [PMID: 15027864] ↓ inhibits Mechanistic DGIdb
VIPIVOTIDE TETRAXETAN ↓ inhibits Mechanistic DGIdb
CAPROMAB PENDETIDE ? unclear Mechanistic DGIdb
DOCETAXEL ANHYDROUS ↓ inhibits Mechanistic DGIdb
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN ? unclear Mechanistic DGIdb
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ~ modulates Mechanistic DGIdb
YTTRIUM Y 90 CAPROMAB PENDETIDE ~ modulates Mechanistic DGIdb
HUJ591 111IN ~ modulates Mechanistic DGIdb
CLAVULANIC ACID ? unclear Mechanistic DGIdb
THERAPEUTIC CORTICOSTEROID ? unclear Mechanistic DGIdb
IMMUNOTOXIN ? unclear Mechanistic DGIdb
CHEMBL51979 ↓ inhibits Mechanistic 43000.0 nM (IC50) ChEMBL
CHEMBL47009 ↓ inhibits Mechanistic 0.3 nM (IC50) ChEMBL
CHEMBL65043 ↓ inhibits Mechanistic 220.0 nM (IC50) ChEMBL
CHEMBL433298 ↓ inhibits Mechanistic 940.0 nM (IC50) ChEMBL
CHEMBL432726 ↓ inhibits Mechanistic 4000.0 nM (IC50) ChEMBL
CHEMBL63454 ↓ inhibits Mechanistic 1200.0 nM (IC50) ChEMBL
CHEMBL303352 ↓ inhibits Mechanistic 90.0 nM (IC50) ChEMBL
CHEMBL64901 ↓ inhibits Mechanistic 82.0 nM (IC50) ChEMBL
CHEMBL65860 ↓ inhibits Mechanistic 20000.0 nM (IC50) ChEMBL
CHEMBL304885 ↓ inhibits Mechanistic 2600.0 nM (IC50) ChEMBL
CHEMBL60317 ↓ inhibits Mechanistic 1100.0 nM (IC50) ChEMBL
CHEMBL61882 ↓ inhibits Mechanistic 6500.0 nM (IC50) ChEMBL
CHEMBL294565 ↓ inhibits Mechanistic 1400.0 nM (IC50) ChEMBL

Showing top 40 of 188 agents ranked by evidence tier.

KLK3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MILVEXIAN ↓ inhibits Mechanistic DGIdb
HUMAN C1-ESTERASE INHIBITOR ↓ inhibits Mechanistic DGIdb
AVORALSTAT ↓ inhibits Mechanistic DGIdb
APROTININ ↓ inhibits Mechanistic DGIdb
SEBETRALSTAT ↓ inhibits Mechanistic DGIdb
BEROTRALSTAT ↓ inhibits Mechanistic DGIdb
COMPOUND 11 [PMID: 16413183] ↓ inhibits Mechanistic DGIdb
BEROTRALSTAT HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ANTITHROMBIN III ? unclear Mechanistic DGIdb
LANADELUMAB ↓ inhibits Mechanistic DGIdb
ECALLANTIDE ↓ inhibits Mechanistic DGIdb
CHEMBL8108 ↓ inhibits Mechanistic 12000.0 nM (IC50) ChEMBL
CHEMBL268367 ↓ inhibits Mechanistic 7200.0 nM (IC50) ChEMBL
CHEMBL559015 ↓ inhibits Mechanistic 61.0 nM (Ki) ChEMBL
CHEMBL289395 ↓ inhibits Mechanistic 5000.0 nM (Ki) ChEMBL
CHEMBL125153 ↓ inhibits Mechanistic 1300.0 nM (Ki) ChEMBL
CHEMBL127909 ↓ inhibits Mechanistic 110.0 nM (Ki) ChEMBL
CHEMBL126707 ↓ inhibits Mechanistic 600.0 nM (Ki) ChEMBL
CHEMBL339902 ↓ inhibits Mechanistic 800.0 nM (Ki) ChEMBL
CHEMBL96433 ↓ inhibits Mechanistic 1.9 nM (Ki) ChEMBL
CHEMBL127407 ↓ inhibits Mechanistic 1300.0 nM (Ki) ChEMBL
CHEMBL127278 ↓ inhibits Mechanistic 4800.0 nM (Ki) ChEMBL
CHEMBL107955 ↓ inhibits Mechanistic 7200.0 nM (Ki) ChEMBL
SEPIMOSTAT MESYLATE ↓ inhibits Mechanistic 570.0 nM (Ki) ChEMBL
CHEMBL107627 ↓ inhibits Mechanistic 7300.0 nM (Ki) ChEMBL
CHEMBL107911 ↓ inhibits Mechanistic 35000.0 nM (Ki) ChEMBL
CHEMBL107282 ↓ inhibits Mechanistic 27000.0 nM (Ki) ChEMBL
CHEMBL319035 ↓ inhibits Mechanistic 22000.0 nM (Ki) ChEMBL
CHEMBL322901 ↓ inhibits Mechanistic 15000.0 nM (Ki) ChEMBL
CHEMBL107743 ↓ inhibits Mechanistic 97000.0 nM (Ki) ChEMBL
CHEMBL322165 ↓ inhibits Mechanistic 3300.0 nM (Ki) ChEMBL
CHEMBL107392 ↓ inhibits Mechanistic 58000.0 nM (Ki) ChEMBL
CHEMBL176243 ↓ inhibits Mechanistic 500.0 nM (IC50) ChEMBL
CHEMBL175130 ↓ inhibits Mechanistic 300.0 nM (IC50) ChEMBL
CHEMBL369086 ↓ inhibits Mechanistic 500.0 nM (IC50) ChEMBL
CHEMBL176671 ↓ inhibits Mechanistic 640.0 nM (IC50) ChEMBL
CHEMBL174558 ↓ inhibits Mechanistic 380.0 nM (IC50) ChEMBL
CHEMBL174499 ↓ inhibits Mechanistic 130.0 nM (IC50) ChEMBL
CHEMBL369681 ↓ inhibits Mechanistic 790.0 nM (IC50) ChEMBL
CHEMBL367953 ↓ inhibits Mechanistic 560.0 nM (IC50) ChEMBL

Showing top 40 of 208 agents ranked by evidence tier.

PARP1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIRAPARIB ↓ inhibits Mechanistic DGIdb
VELIPARIB ↓ inhibits Mechanistic DGIdb
4-[3-(1,4-DIAZEPAN-1-YLCARBONYL)-4-FLUOROBENZYL]PHTHALAZIN-1(2H)-ONE ↓ inhibits Mechanistic DGIdb
PAMIPARIB ↓ inhibits Mechanistic DGIdb
OLAPARIB ↓ inhibits Mechanistic DGIdb
COMPOUND 5 [TOMASSI ET AL., 2020] ↓ inhibits Mechanistic DGIdb
COMPOUND 9 [LIN ET AL., 2023] ↓ inhibits Mechanistic DGIdb
INIPARIB ↓ inhibits Mechanistic DGIdb
AZ1366 ↓ inhibits Mechanistic DGIdb
DUAL VEGFR/PARP INHIBITOR 14B ↓ inhibits Mechanistic DGIdb
NIACIN ? unclear Mechanistic DGIdb
2X-121 ↓ inhibits Mechanistic DGIdb
AMELPARIB DIHYDROCHLORIDE DIHYDRATE ↓ inhibits Mechanistic DGIdb
CEP-9722 ? unclear Mechanistic DGIdb
ORAL AZACITIDINE ? unclear Mechanistic DGIdb
RUCAPARIB PHOSPHATE ↓ inhibits Mechanistic DGIdb
AG14361 ↓ inhibits Mechanistic DGIdb
ME0328 ↓ inhibits Mechanistic DGIdb
SARUPARIB ↓ inhibits Mechanistic DGIdb
SENAPARIB ↓ inhibits Mechanistic DGIdb
NIRAPARIB TOSYLATE ? unclear Mechanistic DGIdb
TALAZOPARIB ↓ inhibits Mechanistic DGIdb
PJ34 ↓ inhibits Mechanistic DGIdb
TALAZOPARIB TOSYLATE ↓ inhibits Mechanistic DGIdb
PARP1 INHIBITOR (S)-G9 ↓ inhibits Mechanistic DGIdb
NICARAVEN ? unclear Mechanistic DGIdb
PARP-1/2 INHIBITOR ABT-767 ? unclear Mechanistic DGIdb
INO-1001 ? unclear Mechanistic DGIdb
BGP-15 ? unclear Mechanistic DGIdb
RUCAPARIB ↓ inhibits Mechanistic DGIdb
TRABECTEDIN ? unclear Mechanistic DGIdb
VENADAPARIB ↓ inhibits Mechanistic DGIdb
FLUZOPARIB ↓ inhibits Mechanistic DGIdb
MC2050 ↓ inhibits Mechanistic DGIdb
PARP INHIBITOR E7016 ? unclear Mechanistic DGIdb
LERZEPARIB ↓ inhibits Mechanistic DGIdb
CICLOPIROX ↓ inhibits Mechanistic DGIdb
E-7016 ↓ inhibits Mechanistic DGIdb
RUCAPARIB CAMSYLATE ↓ inhibits Mechanistic DGIdb
PALACAPARIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 207 agents ranked by evidence tier.

PTEN

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
VS-5584 ? unclear Mechanistic DGIdb
PLX-4720 ? unclear Mechanistic DGIdb
OSIMERTINIB ? unclear Mechanistic DGIdb
ERDAFITINIB ? unclear Mechanistic DGIdb
EVEROLIMUS ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
IPATASERTIB ? unclear Mechanistic DGIdb
TRASTUZUMAB ? unclear Mechanistic DGIdb
VISTUSERTIB ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL4439276 ? unclear Mechanistic DGIdb
ZSTK474 ? unclear Mechanistic DGIdb
DORDAVIPRONE ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
GEDATOLISIB ? unclear Mechanistic DGIdb
ANTINEOPLASTIC AGENT ? unclear Mechanistic DGIdb
ERLOTINIB ? unclear Mechanistic DGIdb
TEMSIROLIMUS ? unclear Mechanistic DGIdb
NAVITOCLAX ? unclear Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
OXALIPLATIN ? unclear Mechanistic DGIdb
EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR ? unclear Mechanistic DGIdb
IPILIMUMAB ? unclear Mechanistic DGIdb
ALPELISIB ? unclear Mechanistic DGIdb
ABT-737 ? unclear Mechanistic DGIdb
PILARALISIB ? unclear Mechanistic DGIdb
FLUOROURACIL ? unclear Mechanistic DGIdb
CX-6258 ? unclear Mechanistic DGIdb
PICTILISIB ? unclear Mechanistic DGIdb
SELUMETINIB ? unclear Mechanistic DGIdb
TAS0612 ? unclear Mechanistic DGIdb
TASELISIB ? unclear Mechanistic DGIdb
LETROZOLE ? unclear Mechanistic DGIdb
VOXTALISIB ? unclear Mechanistic DGIdb
FULVESTRANT ? unclear Mechanistic DGIdb
ATEZOLIZUMAB ? unclear Mechanistic DGIdb
IZORLISIB ? unclear Mechanistic DGIdb
CETUXIMAB ? unclear Mechanistic DGIdb
PI3K/BET INHIBITOR LY294002 ? unclear Mechanistic DGIdb
SIROLIMUS ? unclear Mechanistic DGIdb
BEVACIZUMAB ? unclear Mechanistic DGIdb

Showing top 40 of 155 agents ranked by evidence tier.

SRD5A2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FINASTERIDE ↓ inhibits Mechanistic 1.2 nM (IC50) DGIdb
DUTASTERIDE ↓ inhibits Mechanistic DGIdb
ABIRATERONE ACETATE ↓ inhibits Mechanistic DGIdb
CHEMBL25081 ↓ inhibits Mechanistic 260.0 nM (Ki) ChEMBL
CHEMBL99615 ↓ inhibits Mechanistic 122.0 nM (IC50) ChEMBL
CHEMBL97266 ↓ inhibits Mechanistic 20000.0 nM (Ki) ChEMBL
CHEMBL138580 ↓ inhibits Mechanistic 9000.0 nM (IC50) ChEMBL
CHEMBL2111948 ↓ inhibits Mechanistic 16000.0 nM (IC50) ChEMBL
CHEMBL2111947 ↓ inhibits Mechanistic 10000.0 nM (IC50) ChEMBL
EPRISTERIDE ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL24464 ↓ inhibits Mechanistic 437.0 nM (IC50) ChEMBL
CHEMBL2311155 ↓ inhibits Mechanistic 83.9 nM (IC50) ChEMBL
CHEMBL277403 ↓ inhibits Mechanistic 192.0 nM (IC50) ChEMBL
CHEMBL36573 ↓ inhibits Mechanistic 172.0 nM (IC50) ChEMBL
CHEMBL283564 ↓ inhibits Mechanistic 387.0 nM (IC50) ChEMBL
TUROSTERIDE ↓ inhibits Mechanistic 55.0 nM (IC50) ChEMBL
CHEMBL24191 ↓ inhibits Mechanistic 25.2 nM (IC50) ChEMBL
CHEMBL24958 ↓ inhibits Mechanistic 1390.0 nM (IC50) ChEMBL
CHEMBL24470 ↓ inhibits Mechanistic 256.0 nM (IC50) ChEMBL
CHEMBL2298601 ↓ inhibits Mechanistic 1.9 nM (IC50) ChEMBL
CHEMBL285599 ↓ inhibits Mechanistic 0.2 nM (IC50) ChEMBL
CHEMBL262635 ↓ inhibits Mechanistic 41.0 nM (IC50) ChEMBL
CHEMBL25196 ↓ inhibits Mechanistic 2.9 nM (IC50) ChEMBL
CHEMBL24291 ↓ inhibits Mechanistic 7.1 nM (IC50) ChEMBL
CHEMBL284645 ↓ inhibits Mechanistic 1553.0 nM (IC50) ChEMBL
CHEMBL25083 ↓ inhibits Mechanistic 36.0 nM (IC50) ChEMBL
CHEMBL25282 ↓ inhibits Mechanistic 212.0 nM (IC50) ChEMBL
CHEMBL280954 ↓ inhibits Mechanistic 69.0 nM (IC50) ChEMBL
CHEMBL25193 ↓ inhibits Mechanistic 4.0 nM (IC50) ChEMBL
CHEMBL24193 ↓ inhibits Mechanistic 218.0 nM (IC50) ChEMBL
CHEMBL280387 ↓ inhibits Mechanistic 428.0 nM (IC50) ChEMBL
CHEMBL25072 ↓ inhibits Mechanistic 0.2 nM (IC50) ChEMBL
CHEMBL24465 ↓ inhibits Mechanistic 0.4 nM (IC50) ChEMBL
CHEMBL279206 ↓ inhibits Mechanistic 23.0 nM (IC50) ChEMBL
CHEMBL25593 ↓ inhibits Mechanistic 1218.0 nM (IC50) ChEMBL
CHEMBL25093 ↓ inhibits Mechanistic 10.0 nM (Ki) ChEMBL
CHEMBL278860 ↓ inhibits Mechanistic 381.0 nM (IC50) ChEMBL
CHEMBL25448 ↓ inhibits Mechanistic 154.0 nM (IC50) ChEMBL
CHEMBL285439 ↓ inhibits Mechanistic 6300.0 nM (IC50) ChEMBL
CHEMBL412425 ↓ inhibits Mechanistic 0.12 nM (IC50) ChEMBL

Showing top 40 of 145 agents ranked by evidence tier.

TMPRSS2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MM3122 ↓ inhibits Mechanistic DGIdb
CAMOSTAT ↓ inhibits Mechanistic 1000.0 nM (EC50) DGIdb
OTAMIXABAN ↓ inhibits Mechanistic 620.0 nM (IC50) DGIdb
I-432 ↓ inhibits Mechanistic DGIdb
N-0385 ↓ inhibits Mechanistic DGIdb
NAFAMOSTAT ↓ inhibits Mechanistic 1.0 nM (IC50) DGIdb
COMPOUND 5 [PMID: 21741839] ↓ inhibits Mechanistic DGIdb
N-0920 ↓ inhibits Mechanistic DGIdb
CHEMBL1229259 ↓ inhibits Mechanistic 20.0 nM (Ki) ChEMBL
CHEMBL1809250 ↓ inhibits Mechanistic 53.0 nM (Ki) ChEMBL
CHEMBL1809251 ↓ inhibits Mechanistic 68.0 nM (Ki) ChEMBL
CHEMBL3219102 ↓ inhibits Mechanistic 3.0 nM (Ki) ChEMBL
CHEMBL3219101 ↓ inhibits Mechanistic 3.0 nM (Ki) ChEMBL
CHEMBL3219100 ↓ inhibits Mechanistic 3.0 nM (Ki) ChEMBL
CHEMBL3219103 ↓ inhibits Mechanistic 3.0 nM (Ki) ChEMBL
CHEMBL3219079 ↓ inhibits Mechanistic 0.9 nM (Ki) ChEMBL
CHEMBL3219087 ↓ inhibits Mechanistic 1.0 nM (Ki) ChEMBL
PROPAMIDINE ↓ inhibits Mechanistic 9000.0 nM (IC50) ChEMBL
PENTAMIDINE ↓ inhibits Mechanistic 1200.0 nM (IC50) ChEMBL
DEBRISOQUIN ↓ inhibits Mechanistic 70000.0 nM (IC50) ChEMBL
CHEMBL5270157 ↓ inhibits Mechanistic 4000.0 nM (IC50) ChEMBL
CHEMBL5271456 ↓ inhibits Mechanistic 9000.0 nM (IC50) ChEMBL
CHEMBL5275059 ↓ inhibits Mechanistic 20000.0 nM (IC50) ChEMBL
CHEMBL5270536 ↓ inhibits Mechanistic 20000.0 nM (IC50) ChEMBL
CHEMBL5285196 ↓ inhibits Mechanistic 3400.0 nM (IC50) ChEMBL
CHEMBL5266850 ↓ inhibits Mechanistic 4000.0 nM (IC50) ChEMBL
CHEMBL5275526 ↓ inhibits Mechanistic 20000.0 nM (IC50) ChEMBL
CHEMBL5287275 ↓ inhibits Mechanistic 12000.0 nM (IC50) ChEMBL
TANNIC ACID ↓ inhibits Mechanistic 2310.0 nM (IC50) ChEMBL
DIMINAZENE ↓ inhibits Mechanistic 1350.0 nM (IC50) ChEMBL
CHEMBL1185793 ↓ inhibits Mechanistic 70.0 nM (IC50) ChEMBL
GABEXATE ↓ inhibits Mechanistic 130.0 nM (IC50) ChEMBL
CHEMBL147503 ↓ inhibits Mechanistic 1240.0 nM (IC50) ChEMBL
CHEMBL5561725 ↓ inhibits Mechanistic 22.0 nM (IC50) ChEMBL
CHEMBL5555448 ↓ inhibits Mechanistic 2.5 nM (IC50) ChEMBL
CHEMBL5562350 ↓ inhibits Mechanistic 14.0 nM (IC50) ChEMBL
CHEMBL5558547 ↓ inhibits Mechanistic 1.2 nM (IC50) ChEMBL
CHEMBL5560759 ↓ inhibits Mechanistic 9.8 nM (IC50) ChEMBL
CHEMBL5564865 ↓ inhibits Mechanistic 16.0 nM (IC50) ChEMBL
CHEMBL5557087 ↓ inhibits Mechanistic 16.0 nM (IC50) ChEMBL

Showing top 40 of 69 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Prostate Cancer: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro) Recruiting
NCT07365423 Phase: 2 Started: 2026-04-24

TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatment with curative intent. When local salvage strategies have been exhausted, recurrence usually reflects micro-metastatic disease without cle...

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer Recruiting
NCT07310433 Phase: 2 Started: 2026-05-01

Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who received Dapagliflozin together with standard anti-cancer treatment, androgen ...

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) Active Not Recruiting
NCT04597125 Phase: 4 Started: 2020-11-09

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of ARPI therapy. Meanwhile researchers want t...

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA Active Not Recruiting
NCT04015622 Phase: 2 Started: 2020-10-07

The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction \<2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in sub...

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer Recruiting
NCT05997615 Phase: 1 Started: 2023-08-10

There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment. This is an early development study of VIR-5500 in men with prostate cancer. In this study...

Phase 2 Clinical Trial of 177Lu-P17-088 for mAPMR Prostate Cancer Active Not Recruiting
NCT07562438 Phase: 2 Started: 2026-04-29

PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 177Lu-labeled P17-088 for treating patients with PSMA-positive metastatic androgen pathway modulation ...

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer Recruiting
NCT07339267 Phase: 1 Started: 2026-01-20

In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT). Prednisone is a steroid, and ADT is already given to the men as their standard of care for prostate cancer. The main aims of the study are to ch...

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients Active Not Recruiting
NCT05515978 Phase: Early 1 Started: 2022-10-10

Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation of metformin for these off-label indications is variable, often at the level of the provider. Multi...

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) Recruiting
NCT07244341 Phase: 1 Started: 2025-12-03

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss Recruiting
NCT05593497 Phase: 2 Started: 2024-05-31

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. ...

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. Completed
NCT04655365 Phase: 2 Started: 2022-03-22

This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per institutional standard of care conventional imaging

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy Recruiting
NCT07609225 Phase: Early 1 Started: 2026-10-16

This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if C...

Phase 2 Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer Active Not Recruiting
NCT07117760 Phase: 2 Started: 2025-04-22

PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 225Ac-labeled LNC1011 for treating patients with PSMA-positive metastatic castration-resistant prostat...

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer Recruiting
NCT07570979 Phase: 1 Started: 2026-05-25

The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastati...

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer Recruiting
NCT07181161 Phase: 1/2 Started: 2025-10-01

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

Agents Found By Disease-Level Search

Searched directly from “Prostate Cancer” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

47 agents shown (approved or with trial evidence) — 36 not found by the gene-target search above.

DocetaxelNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00165399 NCT00004001 NCT00005096

DegarelixNOT in gene-target list

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00268892 NCT00268892 NCT00268892

Apalutamide

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT03371719 NCT03767244 NCT07406282

Abiraterone Acetate

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01637402 NCT07198633 NCT07406282

enzalutamide

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT07198633 NCT07406282 NCT02407054

Radium-223 dichloride (Xofigo, BAY88-8223)NOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT01565746 NCT01565746 NCT01565746

Estramustine

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00165399 NCT00004001

Immunotherapy allogeneic GM-CSF secreting cellular vaccineNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00140387 NCT00140348

68Ga-PSMA-11NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05670106 NCT02673151

Bone scanNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT03493945 NCT07200830

Computed TomographyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07200830 NCT07164027

Darolutamide

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05762536 NCT07406282

prednisone

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00004001 NCT01637402

SM88 (Cohort 1)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02796898

SM88 (Cohort 2)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02796898

sodium seleniteNOT in gene-target list

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02184533

Ga-68 PSMA11NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03768349

F-18 PSMA 1007NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03768349

BafetinibNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01215799

High Dose Rate MonotherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05665738

PEG Hydrogel (SpaceOAR)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02212548

CasodexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00165399

ZoladexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00165399

Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patientsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06461793

recombinant interferon alfaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00005847

estramustine phosphate sodium

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00005847

isotretinoin

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00005847

mitoxantrone hydrochloride

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00005847

paclitaxelNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00005847

vinorelbine ditartrateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00005847

DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852007

JUR-003NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07824349

Leuprorelin SRNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01122121

Flutamide

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01122121

Community Health Worker supportNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05301114

bintrafusp alfa (M7824)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03493945

N-803NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03493945

MVA-BN-BrachyuryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03493945

FPV-BrachyuryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03493945

EpacadostatNOT in gene-target list

Phase 1/2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03493945

AcetaminophenNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03493945

IbuprofenNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03493945

NaproxenNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03493945

EKGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03493945

CT chest, abdomen and pelvisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03493945

Degarelix acetate, Leuprolide acetateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01344564

Carboplatin

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04038502

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.